Abstract
As many biosimilars come to market in the next several years, their use in oncology will play an important role in the future care of patients with cancer. ASCO is committed to providing education and guidance to the oncology community on the use of biosimilars in the cancer setting; therefore, ASCO has developed this statement to offer guidance in the following areas: (1) naming, labeling, and other regulatory considerations, (2) safety and efficacy of biosimilars, (3) interchangeability, switching, and substitution, (4) value of biosimilars, and (5) prescriber and patient education.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1260-1265 |
| Number of pages | 6 |
| Journal | Journal of Clinical Oncology |
| Volume | 36 |
| Issue number | 12 |
| DOIs | |
| State | Published - Apr 20 2018 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'American society of clinical oncology statement: Biosimilars in oncology'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver